

# World Journal of *Clinical Cases*

*World J Clin Cases* 2021 February 26; 9(6): 1247-1498



**EDITORIAL**

- 1247 Interactive platform for peer review: A proposal to improve the current peer review system  
*Emile SH*

**MINIREVIEWS**

- 1251 Animal models of cathartic colon  
*Meng YY, Li QD, Feng Y, Liu J, Wang EK, Zhong L, Sun QL, Yuan JY*

**ORIGINAL ARTICLE****Case Control Study**

- 1259 New indicators in evaluation of hemolysis, elevated liver enzymes, and low platelet syndrome: A case-control study  
*Kang SY, Wang Y, Zhou LP, Zhang H*

**Retrospective Study**

- 1271 Analysis of hospitalization costs related to fall injuries in elderly patients  
*Su FY, Fu ML, Zhao QH, Huang HH, Luo D, Xiao MZ*

- 1284 Effect of alprostadil in the treatment of intensive care unit patients with acute renal injury  
*Jia Y, Liu LL, Su JL, Meng XH, Wang WX, Tian C*

**Clinical Trials Study**

- 1293 Etomidate *vs* propofol in coronary heart disease patients undergoing major noncardiac surgery: A randomized clinical trial  
*Dai ZL, Cai XT, Gao WL, Lin M, Lin J, Jiang YX, Jiang X*

**Observational Study**

- 1304 Healthy individuals *vs* patients with bipolar or unipolar depression in gray matter volume  
*Zhang YN, Li H, Shen ZW, Xu C, Huang YJ, Wu RH*
- 1318 Impact of metabolism-related mutations on the heart rate of gastric cancer patients after peritoneal lavage  
*Yuan Y, Yao S, Luo GH, Zhang XY*

**CASE REPORT**

- 1329 Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report  
*He SY, Lin QF, Chen J, Yu GP, Zhang JL, Shen D*

- 1336** Esophageal superficial adenosquamous carcinoma resected by endoscopic submucosal dissection: A rare case report  
*Liu GY, Zhang JX, Rong L, Nian WD, Nian BX, Tian Y*
- 1343** Do medullary thyroid carcinoma patients with high calcitonin require bilateral neck lymph node clearance? A case report  
*Gan FJ, Zhou T, Wu S, Xu MX, Sun SH*
- 1353** Femoral epithelioid hemangioendothelioma detected with magnetic resonance imaging and positron emission tomography/computed tomography: A case report  
*Zhao HG, Zhang KW, Hou S, Dai YY, Xu SB*
- 1359** Noninvasive tools based on immune biomarkers for the diagnosis of central nervous system graft-vs-host disease: Two case reports and a review of the literature  
*Lyu HR, He XY, Hao HJ, Lu WY, Jin X, Zhao YJ, Zhao MF*
- 1367** Periodontally accelerated osteogenic orthodontics with platelet-rich fibrin in an adult patient with periodontal disease: A case report and review of literature  
*Xu M, Sun XY, Xu JG*
- 1379** Subtalar joint pigmented villonodular synovitis misdiagnosed at the first visit: A case report  
*Zhao WQ, Zhao B, Li WS, Assan I*
- 1386** Wilson disease – the impact of hyperimmunity on disease activity: A case report  
*Stremmel W, Longerich T, Liere R, Vacata V, van Helden J, Weiskirchen R*
- 1394** Unexplained elevation of erythrocyte sedimentation rate in a patient recovering from COVID-19: A case report  
*Pu SL, Zhang XY, Liu DS, Ye BN, Li JQ*
- 1402** Thoracic pyogenic infectious spondylitis presented as pneumothorax: A case report  
*Cho MK, Lee BJ, Chang JH, Kim YM*
- 1408** Unilateral pulmonary hemorrhage caused by negative pressure pulmonary edema: A case report  
*Park HJ, Park SH, Woo UT, Cho SY, Jeon WJ, Shin WJ*
- 1416** Osseous Rosai-Dorfman disease of tibia in children: A case report  
*Vithran DTA, Wang JZ, Xiang F, Wen J, Xiao S, Tang WZ, Chen Q*
- 1424** Abdominopelvic leiomyoma with large ascites: A case report and review of the literature  
*Wang YW, Fan Q, Qian ZX, Wang JJ, Li YH, Wang YD*
- 1433** Unusual presentation of granulomatosis with polyangiitis causing periaortitis and consequent subclavian steal syndrome: A case report  
*Cho U, Kim SK, Ko JM, Yoo J*
- 1439** Postoperative discal pseudocyst and its similarities to discal cyst: A case report  
*Fu CF, Tian ZS, Yao LY, Yao JH, Jin YZ, Liu Y, Wang YY*

- 1446** Treatment of oral lichen planus by surgical excision and acellular dermal matrix grafting: Eleven case reports and review of literature  
*Fu ZZ, Chen LQ, Xu YX, Yue J, Ding Q, Xiao WL*
- 1455** Nonalcoholic fatty liver disease as a risk factor for cytomegalovirus hepatitis in an immunocompetent patient: A case report  
*Khiatah B, Nasrollah L, Covington S, Carlson D*
- 1461** Early reoccurrence of traumatic posterior atlantoaxial dislocation without fracture: A case report  
*Sun YH, Wang L, Ren JT, Wang SX, Jiao ZD, Fang J*
- 1469** Intrahepatic cholangiocarcinoma is more complex than we thought: A case report  
*Zeng JT, Zhang JF, Wang Y, Qing Z, Luo ZH, Zhang YL, Zhang Y, Luo XZ*
- 1475** Congenital hepatic fibrosis in a young boy with congenital hypothyroidism: A case report  
*Xiao FF, Wang YZ, Dong F, Li XL, Zhang T*
- 1483** Polidocanol sclerotherapy for multiple gastrointestinal hemangiomas: A case report  
*Yao H, Xie YX, Guo JY, Wu HC, Xie R, Shi GQ*
- 1490** Gastrointestinal stromal tumor with multisegmental spinal metastases as first presentation: A case report and review of the literature  
*Kong Y, Ma XW, Zhang QQ, Zhao Y, Feng HL*

**ABOUT COVER**

Editorial Board Member of *World Journal of Clinical Cases*, Dr. Quach is an Associate Professor of Gastroenterology at the University of Medicine and Pharmacy at Hochiminh City, Viet Nam, where he received his MD in 1997 and his PhD in 2011. Dr. Quach has published more than 100 reviews and original papers in local and international journals. He has received several awards, including Outstanding Presentation at the Biannual Scientific Congress of Vietnamese Nationwide Medical Schools, Medal of Creativeness from the Vietnamese Central Youth League, etc. Currently, he serves as a Vice President of the Vietnam Association of Gastroenterology and Secretary General of the Vietnam Federation for Digestive Endoscopy. (L-Editor: Filipodia)

**AIMS AND SCOPE**

The primary aim of *World Journal of Clinical Cases* (*WJCC*, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

*WJCC* mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

**INDEXING/ABSTRACTING**

The *WJCC* is now indexed in Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, PubMed, and PubMed Central. The 2020 Edition of Journal Citation Reports® cites the 2019 impact factor (IF) for *WJCC* as 1.013; IF without journal self cites: 0.991; Ranking: 120 among 165 journals in medicine, general and internal; and Quartile category: Q3. The *WJCC*'s CiteScore for 2019 is 0.3 and Scopus CiteScore rank 2019: General Medicine is 394/529.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Ji-Hong Liu*; Production Department Director: *Xiang Li*; Editorial Office Director: *Jin-Lai Wang*.

**NAME OF JOURNAL**

*World Journal of Clinical Cases*

**ISSN**

ISSN 2307-8960 (online)

**LAUNCH DATE**

April 16, 2013

**FREQUENCY**

Thrice Monthly

**EDITORS-IN-CHIEF**

Dennis A Bloomfield, Sandro Vento, Bao-Gan Peng

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

**PUBLICATION DATE**

February 26, 2021

**COPYRIGHT**

© 2021 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

## Nonalcoholic fatty liver disease as a risk factor for cytomegalovirus hepatitis in an immunocompetent patient: A case report

Bashar Khiatah, Laya Nasrollah, Stephen Covington, Deborah Carlson

**ORCID number:** Bashar Khiatah 0000-0002-6870-8094; Deborah Carlson 0000-0001-6392-3337.

**Author contributions:** Khiatah B wrote the main manuscript; Nasrollah L, Covington S and Carlson D provided expert input and editing; all of the authors provided direct care to the patient.

**Informed consent statement:** Informed consent was taken from the patient.

**Conflict-of-interest statement:** All authors declare no conflict of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and

**Bashar Khiatah, Deborah Carlson,** Internal Medicine, Community Memorial Hospital, Ventura, CA 93003, United States

**Laya Nasrollah, Stephen Covington,** Department of Gastroenterology, Community Memorial Hospital, Ventura, CA 93003, United States

**Corresponding author:** Bashar Khiatah, MD, Doctor, Internal Medicine, Community Memorial Hospital, 147 N Brent Street, Ventura, CA 93003, United States. [bkhiatah@gmail.com](mailto:bkhiatah@gmail.com)

### Abstract

#### BACKGROUND

Almost 80 percent of adults in the United States have had cytomegalovirus (CMV) infection by age 40. The number of symptomatic CMV hepatitis cases has been increasing along with non-alcoholic fatty liver disease (NAFLD) cases in the United States that is estimated to be 25 percent of the population. In this paper, we try to link these two entities together.

#### CASE SUMMARY

In this case report, we describe a young female who presented with fever, nausea, and vomiting who was found to have NAFLD and CMV hepatitis that was treated supportively.

#### CONCLUSION

In this case report, we describe NAFLD as a risk factor for CMV hepatitis and discuss the possible impact on clinical practice. We believe, it is essential to consider NAFLD and its disease mechanisms' localized immuno-suppression, as a risk factor of CMV hepatitis and severe coronavirus disease 2019 infection.

**Key Words:** Non-alcoholic fatty liver disease; Cytomegalovirus hepatitis; Immunocompetent; Female health; Global impact; Hepatology; Case report

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** It is essential to consider non-alcoholic fatty liver disease and its disease mechanisms' localized immunosuppression, as a risk factor of cytomegalovirus hepatitis and possible other viral diseases. Also, with non-alcoholic fatty liver disease

the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** United States

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): B  
Grade C (Good): 0  
Grade D (Fair): 0  
Grade E (Poor): 0

**Received:** November 4, 2020

**Peer-review started:** November 4, 2020

**First decision:** December 13, 2020

**Revised:** December 13, 2020

**Accepted:** December 27, 2020

**Article in press:** December 27, 2020

**Published online:** February 26, 2021

**P-Reviewer:** Schmitz SMT

**S-Editor:** Zhang L

**L-Editor:** A

**P-Editor:** Zhang YL



raising numbers it is worthwhile to screen for it in high risk population to prevent from it's complications and risks to develop severe viral diseases in case of infection that could be life threatening.

**Citation:** Khiatah B, Nasrollah L, Covington S, Carlson D. Nonalcoholic fatty liver disease as a risk factor for cytomegalovirus hepatitis in an immunocompetent patient: A case report. *World J Clin Cases* 2021; 9(6): 1455-1460

**URL:** <https://www.wjgnet.com/2307-8960/full/v9/i6/1455.htm>

**DOI:** <https://dx.doi.org/10.12998/wjcc.v9.i6.1455>

## INTRODUCTION

Cytomegalovirus (CMV) is a herpesviridae family member that causes a spectrum of human illness that is mostly dependent on the host. Infection in an immunocompetent patient is usually asymptomatic or might present as a mononucleosis syndrome. Occasionally, primary CMV infection can lead to severe organ-specific complications with significant morbidity and mortality<sup>[1,2]</sup>. CMV hepatitis in immunocompetent patients has been reported frequently in the literature, increasing the awareness of this disease<sup>[3]</sup>. Reports over the last decade have informed us that non-alcoholic fatty liver disease (NAFLD) is a multisystem disease affecting multiple extrahepatic organs and regulatory pathways, proving that NAFLD's clinical burden is not limited to liver-related morbidity and mortality<sup>[4]</sup>. NAFLD is an excessive infiltration of fat in the liver in individuals not consuming or consuming in small amounts of alcohol defined as  $\leq 20$  g per day for women and  $\leq 30$  g per day for men. Diagnosis usually requires the elimination of secondary causes of fatty infiltration of the liver, including hepatitis C virus infection, the use of glucocorticoids, celiac disease, Wilson disease, familial hypobetalipoproteinemia, and autoimmune disorders<sup>[5]</sup>.

## CASE PRESENTATION

### Chief complaints

Six-day history of fever, night sweats, myalgia, nausea, and vomiting.

### History of present illness

A 34-year-old Hispanic female presents to the emergency room (ER) with a six-day history of fever, night sweats, myalgia, nausea, and vomiting. Coronavirus disease 2019 testing was negative, and she was sent home on antiemetics. She developed intermittent abdominal pain in the right upper quadrant of 5/10 intensity, sharp, non-radiating associated with mild headache and lightheadedness that prompted her to return to the ER. She has no sick contacts. She is up to date on her vaccinations, monogamous, practices all social distancing precautions, and is a housewife and a mother of 3 healthy children. She denies having pain with any specific foods, including fatty foods, recent travel, IV drug abuse, alcohol, smoking, and all other symptoms. Her only medications were Ondansetron and Acetaminophen.

### History of past illness

Remote history of intermittent asthma.

### Personal and family history

Family history is remarkable for diabetes.

### Physical examination

On physical exam, her body mass index is 33.1 kg/m<sup>2</sup>; she has a temperature of 101.2 F and is mildly tender to palpation in the epigastric area. Otherwise, her physical exam is benign.

### **Laboratory examinations**

Laboratory studies are shown in [Table 1](#) and [2](#).

### **Imaging examinations**

Radiologic studies revealed fatty liver, as shown in [Figure 1](#) and [2](#), compared to normal liver imaging in 2015.

---

## **FINAL DIAGNOSIS**

CMV Hepatitis in the setting of NAFLD. She is admitted for observation and found to have CMV hepatitis, as shown in [Table 1](#) and [2](#).

---

## **TREATMENT**

Supportive treatment with Ibuprofen 400 mg every 6 h for fever.

---

## **OUTCOME AND FOLLOW-UP**

She was discharged home and instructed to follow up with both her primary care doctor and the Gastroenterologist. Education was provided on a low-fat diet, exercise, and the importance of weight loss. One week after discharge, she was seen in the primary clinic for follow up. She reported continuous yet less frequent symptoms of fever, myalgias, and night sweats controlled with Acetaminophen, Ibuprofen, and Ondansetron. Her liver enzymes were trending down. Two weeks after discharge, she was symptom-free with normalized liver enzymes.

---

## **DISCUSSION**

The liver is a unique immune environment containing lymphocytes, monocytes, Kupffer cells, Natural-killers, astrocytes dendritic, and many other immigrant cells associated with the immune system. It is responsible for synthesizing various proteins such as acute-phase proteins, complements, cytokines, chemokines, lipid messengers, and reactive oxygen species. Insulin resistance, oxidative stress, endoplasmic reticulum stress, endotoxins from the intestinal flora, and genetic predispositions are all involved in developing NAFLD, causing an imbalance of the immune system in the liver<sup>[4,5]</sup>. This imbalance translates as an elevation of Interleukin-6 (IL-6), IL-15, IL-17, IL18, Tumor Necrosis Factor-alpha, Interferon gamma-induced protein 10, and Transforming growth factor beta-3<sup>[6]</sup>. A recently published study where authors reported NAFLD's significance as a significant risk factor affecting the severity of coronavirus disease 2019 emphasizes the importance of this imbalance<sup>[6]</sup>.

---

## **CONCLUSION**

Finally, in the United States, with an estimated 25 percent of the population with NAFLD, and almost 80 percent of adults having CMV infection by age 40, it is essential to consider NAFLD and its disease mechanisms' localized immunosuppression, as a risk factor of CMV hepatitis. Further studies and research are required to understand NAFLD as a risk for viral diseases.

**Table 1 Laboratory trend**


	Day 1	Day 2	Day 3 (discharge day)
Hemoglobin (range 12.0-16.0 g/dL)	14.6	12.8	12.6
White blood count (range 4.8-10/8 k/ $\mu$ L)	11.4	8.9	9.0
Platelet count (range 150-400 k/ $\mu$ L)	173	156	162
Serum sodium (range 135-145 mEq/L)	133	133	133
Serum bicarbonate (range 24-30 mEq/L)	25	22	22
Blood urea nitrogen (range 8-26 mg/dL)	6	5	4
Creatinine, serum (range 0.5-1.5 mg/dL)	0.91	0.73	0.81
Protein, serum (g/dL) (range 6.0-8.5 g/dL)	6.7	5.8	5.8
Albumin, serum (g/dL) (range 3.4-4.8 g/dL)	3.1	2.6	2.6
Alanine aminotransferases (range 5-40 unit/L)	319	234	200
Aspartate aminotransferase (range 9-48 unit/L)	210	130	118
Alkaline phosphatase (range 53-128 unit/L)	372	302	314
Total bilirubin (range 0.2-1.2 mg/dL)	1	1.2	1.1
Direct bilirubin (range 0-0.3 mg/dL)	0.4	0.4	0.4

**Table 2 Hepatitis workup**

Test	Result
Hepatitis A IgM	Negative
Hepatitis Be Antigen	Negative
Hepatitis Be antibody	Negative
Hepatitis C	Negative
Hepatitis E antibody IGG	Detected
Hepatitis E antibody IGM	Negative
HIV antibody	Negative
Blood culture	Negative
Urine culture	Negative
Pregnancy test, Urine	Negative
Serum CMV DNA PCR (normal range < 200.00 IU/mL)	13700 IU/mL
Cytomegalovirus IgM (normal range < 29.9 U/mL)	47.7AU/mL
Influenza A and B rapid test	Negative
Epstein-Barr virus DNA PCR (Negative)	Negative
HIV-1/2 antibody/antigen	Negative
SARS-COV-2 IGM/IGG	Negative
Acetaminophen (range 10-30 $\mu$ g/mL)	< 10 $\mu$ g/mL
Antinuclear antibodies	Negative
Anti-smooth muscle antibody	Negative
Anti-mitochondrial	Negative
Tissue transglutaminase antibody	Negative
Liver kidney microsomal assay (negative range $\leq$ 20.0 units)	< 20.0 units
Ferritin	384 ng/mL

Erythrocyte sedimentation rate (range 0-30.0 mm/h)	16 mm/h
24 h Urine Copper (3.0-45.0 µg/d)	48 µg/d
C-reactive protein (0.00-0.80 mg/dL)	5.8 mg/dL

CMV: Cytomegalovirus; PCR: Polymerase chain reaction; SARS-COV-2: Severe acute respiratory syndrome coronavirus; IGG: Immunoglobulin G.



**Figure 1** Intrahepatic vessels appear unremarkable including the hepatic veins. Increased liver echogenicity with moderately enlarged liver most consistent with fatty infiltration. Mild heterogeneous liver around the gallbladder fossa likely related parenchymal sparing in an otherwise fatty liver.



**Figure 2** Magnetic resonance cholangiopancreatography results. Mild hepatosplenomegaly and hepatic steatosis.

## REFERENCES

- 1 **Horwitz CA**, Henle W, Henle G, Snover D, Rudnick H, Balfour HH Jr, Mazur MH, Watson R, Schwartz B, Muller N. Clinical and laboratory evaluation of cytomegalovirus-induced mononucleosis in previously healthy individuals. Report of 82 cases. *Medicine (Baltimore)* 1986; **65**: 124-134 [PMID: [3005799](#) DOI: [10.1097/00005792-198603000-00005](#)]
- 2 **Cohen JI**, Corey GR. Cytomegalovirus infection in the normal host. *Medicine (Baltimore)* 1985; **64**: 100-114 [PMID: [2983175](#) DOI: [10.1097/00005792-198503000-00003](#)]
- 3 **Wreghitt TG**, Teare EL, Sule O, Devi R, Rice P. Cytomegalovirus infection in immunocompetent patients. *Clin Infect Dis* 2003; **37**: 1603-1606 [PMID: [14689339](#) DOI: [10.1086/379711](#)]
- 4 **Byrne CD**, Targher G. NAFLD: a multisystem disease. *J Hepatol* 2015; **62**: S47-S64 [PMID: [25920090](#) DOI: [10.1016/j.jhep.2014.12.012](#)]
- 5 **Kosmalski M**, Mokros L, Kuna P, Witusik A, Pietras T. Changes in the immune system - the key to diagnostics and therapy of patients with non-alcoholic fatty liver disease. *Cent Eur J Immunol* 2018; **43**: 231-239 [PMID: [30135638](#) DOI: [10.5114/ceji.2018.77395](#)]
- 6 **Boettler T**, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Jalan R, Moreau R, Cornberg M, Berg T. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. *JHEP Rep* 2020; **2**: 100169 [PMID: [32835190](#) DOI: [10.1016/j.jhepr.2020.100169](#)]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-3991568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
**Help Desk:** <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

